Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MSH 1001

Next Previous
X
Search
Drug Profile

MSH 1001

Alternative Names: Cardioprotective therapy (KR-31378) - Dongbu Hannong; DNB 001; Glaucoma therapy (DNB-001) - Danube Pharmaceuticals; KR-31378; MSH-1001

Latest Information Update: 27 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Charlesson; Danube Pharmaceuticals; Korea Research Institute of Chemical Technology
  • Class Anti-ischaemics; Antiglaucomas; Neuroprotectants; Small molecules
  • Mechanism of Action KATP channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glaucoma; Ocular hypertension
  • Discontinued Ischaemia; Ischaemic heart disorders

Most Recent Events

  • 08 Oct 2014 No development reported - Preclinical for Glaucoma in USA (Intraocular)
  • 08 Oct 2014 No development reported - Preclinical for Ocular hypertension in USA (Intraocular)
  • 31 Dec 2011 Discontinued - Phase-I for Glaucoma in United Kingdom (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top